#United States #Burlington #Multiomics #Azenta #Sample Management Solutions

Azenta's Q2 Fiscal 2026 Results: Key Insights and Future Plans

On May 5, 2026, Azenta, Inc. released its financial results for the second quarter, which ended on March 31, 2026. The report indicates that the company is undergoing significant changes in response to current market conditions and operational challenges.

Revised Revenue Projections

The total reported revenue from continuing operations for FY 2026 is now expected to fall between approximately $603 million to $621 million. This represents a notable shift from previous forecasts, with organic revenue now anticipated to decline by approximately 2% to increase by 1%. This revision contrasts sharply with earlier projections which estimated growth between 3% to 5%.

Key Performance Metrics

Revenue: For the quarter, Azenta reported $145 million in revenue, a slight increase of 1% from $143 million in the same period last year. However, when accounting for organic growth, there was a decline of 3% primarily due to reduced performance in Multiomics and Sample Management Solutions segments.
Sample Management Solutions revenue stood at $81 million, reflecting a 2% increment year-over-year, while Multiomics revenue remained stable at $64 million.
Earnings Per Share (EPS): The diluted EPS from continuing operations came in at ($3.41), an increase from ($0.43) in Q2 of the previous fiscal year. The EPS reported for total operations was ($3.49), also showing a decline.

Management’s Perspectives

John Marotta, the President and CEO of Azenta, acknowledged the disappointing results, attributing them to operational gaps and a cautious demand environment, particularly in North America. He emphasized that despite these hurdles, there remains resilience in certain areas of the business, particularly within Sample Repository Solutions and Consumables and Instruments.

“###Q2 2026 has revealed critical execution gaps that we need to address promptly, and we are committed to reinforcing our operational discipline,” said Marotta. “Looking forward, our focus is to transform our Multiomics business and consolidate our commercial execution.”

Strategic Adjustments

In light of the revised forecasts, the company has decided to extend the timeline for its long-range plan targets from 2028 to 2029. Marotta believes this approach is prudent given the current economic landscape, as it allows for more time to meet operational enhancements and maintain strategic priorities.

Financial Disturbances

Operating Loss

Azenta experienced an operating loss of $165.8 million, marking a stark contrast to the prior year. The operating expenses rose significantly, reaching $228 million due to a non-cash goodwill impairment charge of $149 million related to reduced evaluations of both the Multiomics and Sample Management Solutions segments.

Adjusted EBITDA

The adjusted EBITDA for continuing operations was reported at $8 million with a margin of 5.4%. Comparatively, this is down from 8.5% in the previous year’s quarter.

Guidance for Fiscal 2026

As the fiscal year progresses, Azenta has set a clear direction moving forward:
Total reported revenue is forecasted between $603 million and $621 million.
Organic revenue is expected to lie between a decline of 2% to an increase of 1%.
Adjusted EBITDA margin projections indicate a potential drop of approximately 125 basis points to flat, compared to previous expectations of about 300 basis points of growth.

Conclusion

Despite the challenges highlighted in the Q2 Fiscal 2026 report, Azenta remains optimistic about its long-term growth prospects. The strategic measures being implemented aim to enhance operational efficiency and capitalize on market opportunities. For investors and stakeholders, the forthcoming earnings call on May 6, 2026, will provide further insights into Azenta's financial performance and strategic roadmap moving ahead.

For more details on the earnings report, please visit Azenta’s Investor Relations page.